Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials

Study answer

What this study found

Omega-3 supplementation did not produce statistically significant reductions in all-cause mortality or restenosis after PCI, although the point estimates suggested a possible modest benefit. All-cause mortality was RR = 0.88, 95% CrI = 0.64, 1.03, with a probability of some benefit of 0.93. Restenosis after PCI was RR = 0.89, 95% CrI = 0.72, 1.05, with a probability of some benefit of 0.90. Safety was generally favorable, but gastrointestinal side effects were more common with omega-3 (RR = 1.29, 95% CrI = 1.02, 1.61), while treatment discontinuation, malignancy, and bleeding were not…

Study & population

Meta-analysis of randomized controlled trials in high-risk cardiovascular patients, including post-myocardial infarction patients, patients with implantable cardioverter-defibrillators, diabetics, and other high-risk cardiovascular groups.

Intervention

Omega-3 fatty acid supplementation was evaluated across trials using EPA, DHA, DPA, or ALA.

Key limitation

Trials were heterogeneous in patient population, omega-3 form, dose, and follow-up duration, which ranged from 1 to 55 months.

View full study detailsView sourceOpen PDF

Original abstract